All Type of News
Will impact of ghost surgery lead to strengthening ‘explanatory obligation’?
The impact of ghost surgeries performed by some plastic surgeons and Samsung Medical Center was finally led to a plain to amend the law about obligation of explanation for performing surgeons.
On the 9th, Assemblype...
Pharmaceutical field’s employment market is hot as sun
As the unemployment problem is getting intensified due to the depression in the real economy overall, the pharmaceutical industry’s job creation capability has drawn attention.
44 of 100 domestic listed companies(44%...
President Park’s firm will towards telemedicine, asking healthcare field for cooperation
Since showing a strong will towards telemedicine, President Geun-hye Park asked the National Assembly and the healthcare industry for cooperation to pass the Amendment to the Medical Law.
At a place where the Meeting...
Domestic pharm companies failed in patent challenges to leukemia therapy ‘Tasigna’
Domestic pharmaceutical companies challenged to a substance patent of ‘Tasigna,’ a Novartis’ chronic myelogenous leukemia therapy, but failed.
According to the industry on the 8th, Kukje Pharm and Navi Pharm applied ...
Abbvie’s another attempt to get health insurance benefit for ‘Duodopa’
A Parkinson’s disease treatment, ‘Duodopa Intestinal Gel,’ made the second challenge for the health insurance registration.
According to the industry concerned on the 9th, Abbvie’s Duodopa(carbidopa, levodopa) which...
Celltrion investing funds into Operation Chromite
As a movie that Celltrion invested KRW 3 billion into, ‘Operation Chromite,’ recorded 5.2 million audiences in 12 days after its release, the Celltrion’s investment returns and promotional effect have attracted attent...
Alcohol epilepsy patients over 50 account for 64.4% of the total
It was observed that most alcohol epilepsy patients caused by drinking are in the 50s. The patients in the 60s were followed closely after.
The National Health Insurance Service(President Sang-cheol Seong) analyzed d...
Leading breast cancer therapy, Herceptin keeps exclusivity by next year
In the domestic breast cancer treatment market, the Roche’s influence is expected to be kept, at least, by 2017.
This is because Celltrion which acquire approval of the Herceptin’s biosimilar, ‘Herzuma,’ has recently...
High influence of Korean biosimilars, raising expectations
The 3 Korean biosimilars that are currently sold in Europe have been evaluated so positively that market shares of the original products are decreasing. This is why there are high expectations on biosimilars and biobe...
Domestic companies’ strategy to avoid ‘Pradaxa’ patent
Domestic pharmaceutical companies are altering strategies on patent suits to develop generics of ‘Pradaxa(generic name: dabigatran).’
As keeping losing on its substance and composition patent nullification trials, th...
